The TCL1 family of oncoproteins: Co-activators of transformation

Nature Reviews Cancer

Volumn 5, Issue 8, 2005, Pages 640-648

  Teitell, Michael A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN KINASE B; PROTEIN T CELL LEUKEMIA 1; PROTEIN T CELL LYMPHOMA 1; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; B LYMPHOCYTE; BINDING SITE; BURKITT LYMPHOMA; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME REARRANGEMENT; CHRONIC LYMPHATIC LEUKEMIA; DOWN REGULATION; EMBRYO DEVELOPMENT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPSTEIN BARR VIRUS; FOLLICULAR LYMPHOMA; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GERM CELL; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE TRANSFORMATION; LYMPHOMA; NONHUMAN; OOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSGENIC MOUSE; VIRUS INFECTION;

ANIMALS; HUMANS; LEUKEMIA; LYMPHOMA; MICE; MODELS, ANIMAL; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS; TRANS-ACTIVATORS;

EID: 23144442026     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1672     Document Type: Review

References (72)

1. Virgilio, L. et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc. Natl Acad. Sci. USA 91, 12530-12534 (1994).
2. Madani, A. et al. Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. Blood 87, 1923-1927 (1996).
3. Narducci, M. G. et al. The murine Tcl1 oncogene: embryonic and lymphoid cell expression. Oncogene 15, 919-926 (1997).
4. Pekarsky, Y. et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc. Natl Acad. Sci. USA 97, 3028-3033 (2000).
5. Laine, J., Kunstle, G., Obata, T., Sha, M. & Noguchi, M. The protooncogene TCL1 is an Akt kinase co-activator. Mol. Cell 6, 395-407 (2000). Together with reference 4, this article shows that TCL1 binds and augments AKT-kinase activity.
6. French, S. W. et al. A modeled hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the cytoplasmic membrane. Biochemistry 41, 6376-6382 (2002).
7. Auguin, D. et al. Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family protooncoproteins. J. Biol. Chem. 279, 35890-35902 (2004). This article provides a structural model for the TCL1-AKT interaction stabilized at the cytoplasmic membrane.
8. Narducci, M. G. et al. TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proc. Natl Acad. Sci. USA 99, 11712-11717 (2002).
9. Kang, S. M. et al. Impaired T and B cell development in Tcl1 deficient mice. Blood 105, 1288-1294 (2005).
10. Kiss, C. et al. T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines. Proc. Natl Acad. Sci. USA 100, 4813-4818 (2003).
11. French, S. W. et al. Sp1 transactivation of the TCL1 oncogene. J. Biol. Chem. 278, 948-955 (2003).
12. Virgilio, L. et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc. Natl Acad. Sci. USA 95, 3885-3889 (1998). Together with references 13-15, this paper shows that TCL1 dysregulation transforms T- and B-lymphocytes.
13. Gritti, C. et al. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood 92, 368-373 (1998). Provides a genetic model for human B-CLL by dysregulated TCL1 expression in B cells.
14. Hoyer, K. K. et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc. Natl Acad. Sci. USA 99, 14392-14397 (2002). Provides a genetic model for human GC B-cell transformation by the dysregulated expression of TCL1 in B- and T-lineage cells.
15. Russo, G. et al. Molecular analysis of at(7;14)(q35;q32) chromosome translocation in a T cell leukemia of a patient with ataxia telangiectasia. Cell 53, 137-144 (1988).
16. Pekarsky, Y., Hallas, C. & Croce, C. M. Molecular basis of mature T-cell leukemia. JAMA 286, 2308-2314 (2001).
17. Pekarsky, Y., Hallas, C. & Croce, C. M. The role of TCL1 in human T-cell leukemia. Oncogene 20, 5638-5643 (2001).
18. Teitell, M. A. in Wiley's Encyclopedia of Molecular Medicine (ed. Creighton, T. E.) 3106-3108 (J. Wiley & Sons, New York, 2002).
19. Pekarsky, Y., Zanesi, N., Aqeilan, R. & Croce, C. M. Tcl1 as a model for lymphomagenesis. Hematol. Oncol. Clin. North Am. 18, 863-79, ix (2004).
20. Stern, M. H. et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor α/δ locus in mature T cell proliferations. Oncogene 8, 2475-483 (1993).
21. Pekarsky, Y., Hallas, C., Isobe, M., Russo, G. & Croce, C. M. Abnormalities at 14q32. 1 in T cell malignancies involve two oncogenes. Proc. Natl Acad. Sci. USA 96, 2949-2951 (1999).
22. Sugimoto, J., Hatakeyama, T., Narducci, M. G., Russo, G. & Isobe, M. Identification of the TCL1/MTCP1-like 1 (TML1) gene from the region next to the TCL1 locus. Cancer Res. 59, 2313-2317 (1999).
23. Hallas, C. et al. Genomic analysis of human and mouse TCL1 loci reveals a complex of tightly clustered genes. Proc. Natl Acad. Sci. USA 96, 14418-14423 (1999).
24. Minami, N., Sasaki, K., Aizawa, A., Miyamoto, M. & Imai, H. Analysis of gene expression in mouse 2-cell embryos using fluorescein differential display: comparison of culture environments. Biol. Reprod. 64, 30-35 (2001).
25. Teague, T. K. et al. Activation changes the spectrum but not the diversity of genes expressed by T cells. Proc. Natl Acad. Sci. USA 96, 12691-12696 (1999).
26. + blastic tumours of skin. Blood 101, 5007-5009 (2003).
27. Teitell, M. et al. TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. Proc. Natl Acad. Sci. USA 496, 9809-9814 (1999). This study is the first to provide a potential oncogenic role for dysregulated TCL1 in human B-cell tumours.
28. Said, J. W. et al. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab. Invest. 81, 555-564 (2001).
29. Muschen, M. et al. Molecular portraits of B cell lineage commitment. Proc. Natl Acad. Sci. USA 99, 10014-10019 (2002).
30. Narducci, M. G. et al. TCL1 is overexpressed in patients affected by adult T-cell leukemias. Cancer Res. 57, 5452-5456 (1997).
31. Hoyer, K. K. et al. TCL1 modulates TCR signal strength and IFNγ levels through PI3K and PKC pathway activation. J. Immunol. 175, 864-873 (2005).
32. Soulier, J. et al. The MTCP-1/c6. 1B gene encodes for a cytoplasmic 8 kD protein overexpressed in T cell leukemia bearing a t(X;14) translocation. Oncogene 9, 3565-3570 (1994).
33. Yuille, M. R. et al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosom. Cancer 30, 336-341 (2001).
34. Chun, H. H. et al. TCL-1, MTCP-1 and TML-1 gene expression profile in non-leukemic clonal proliferations associated with ataxia-telangiectasia. Int. J. Cancer 97, 726-731 (2002).
35. Narducci, M. G. et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res. 60, 2095-2100 (2000).
36. Petrella, T. et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am. J. Clin. Pathol. 122, 307-313 (2004).
37. Klein, U. et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 194, 1625-1638 (2001).
38. Bell, A. & Rickinson, A. B. Epstein-Barr virus, the TCL-1 oncogene and Burkitt's lymphoma. Trends Microbiol. 11, 495-497 (2003).
39. Fu, T. B. et al. Characterization and localization of the TCL-1 oncogene product. Cancer Res. 54, 6297-6301 (1994).
40. Hoh, F. et al. Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel β-barrel topology. Structure 6, 147-155 (1998). Shows that members of the TCL1 gene family encode proteins that have a novel β-barrel structure.
41. Fu, Z. Q. et al. Crystal structure of MTCP-1: implications for role of TCL-1 and MTCP-1 in T cell malignancies. Proc. Natl Acad. Sci. USA 95, 3413-3418 (1998).
42. Petock, J. M. et al. Structure of murine Tcl1 at 2.5 A resolution and implications for the TCL oncogene family. Acta Crystallogr. D Biol. Crystallogr. 57, 1545-1551 (2001).
43. Madani, A. et al. The 8 kD product of the putative oncogene MTCP-1 is a mitochondrial protein. Oncogene 10, 2259-2262 (1995).
44. Bellacosa, A., Testa, J. R., Staal, S. P. & Tsichlis, P. N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254, 274-277 (1991).
45. Datta, S. R., Brunet, A. & Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev. 13, 2905-2927 (1999).
46. Chan, T. O., Rittenhouse, S. E. & Tsichlis, P. N. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu. Rev. Biochem. 68, 965-1014 (1999).
47. Brazil, D. P. & Hemmings, B. A. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci. 26, 657-664 (2001).
48. Hill, M. M., Feng, J. & Hemmings, B. A. Identification of a plasma membrane Raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr. Biol. 12, 1251-1255 (2002).
49. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
50. Burgering, B. M. & Coffer, P. J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376, 599-602 (1995).
51. Franke, T. F., Kaplan, D. R., Cantley, L. C. & Toker, A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate. Science 275, 665-668 (1997).
52. Delcommenne, M. et al. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl Acad. Sci. USA 95, 11211-11216 (1998).
53. Toker, A. & Newton, A. C. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J. Biol. Chem. 275, 8271-8274 (2000).
54. Persad, S. et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J. Biol. Chem. 276, 27462-27469 (2001).
55. Bayascas, J. R. & Alessi, D. R. Regulation of Akt/PKB Ser473 Phosphorylation. Mol. Cell 18, 143-145 (2005).
56. Laine, J., Kunstle, G., Obata, T. & Noguchi, M. Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family. J. Biol. Chem. 277, 3743-3751 (2002).
57. Kunstle, G. et al. Identification of Akt association and oligomerization domains of the Akt kinase co-activator TCL1. Mol. Cell. Biol. 22, 1513-1525 (2002).
58. Gold, M. R. Akt is TCL-ish: implications for B-cell lymphoma. Trends Immunol. 24, 104-108 (2003).
59. Hiromura, M. et al. Inhibition of Akt kinase activity by a peptide spanning the βA strand of the protooncogene TCL1. J. Biol. Chem. 279, 53407-53418 (2004). Shows the first, specific in vitro AKT kinase inhibitor, which consists of a 15-amino acid peptide stretch from the AKT binding domain βA strand of TCL1.
60. Pekarsky, Y. et al. Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proc. Natl Acad. Sci. USA 98, 3690-3694 (2001).
61. Lin, B. et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 116, 527-540 (2004).
62. Malstrom, S., Tili, E., Kappes, D., Ceci, J. D. & Tsichlis, P. N. Tumour induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc. Natl Acad. Sci. USA 98, 14967-14972 (2001).
63. Morse, H. C., 3rd et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 100, 246-258 (2002).
64. Egle, A., Harris, A. W., Bath, M. L., O'Reilly, L. & Cory, S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 103, 2276-2283 (2004).
65. Ramuz, O. et al. Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas. Int. J. Oncol. 26, 151-157 (2005).
66. Suzuki, A. et al. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J. Exp. Med. 197, 657-667 (2003).
67. Anzelon, A. N., Wu, H. & Rickert, R. C. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nature Immunol. 4, 287-294 (2003).
68. Maira, S. M. et al. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 294, 374-380 (2001).
69. Gao, T, Furnari, F. & Newton, A. C. PHLPP: A phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumour growth. Mol. Cell 18, 13-24 (2005).
70. Bayascas, J. R. & Alessi, D. R. Regulation of Akt/PKB Ser473 phosphorylation. Mol. Cell 18, 143-145 (2005).
71. Milburn, C. C. et al. Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem. J. 375, 531-538 (2003).
72. Thomas, C. C., Deak, M., Alessi, D. R. & van Aalten, D. M. High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr. Biol. 12, 1256-1262 (2002).